
CONMED (CNMD) Stock Forecast & Price Target
CONMED (CNMD) Analyst Ratings
Bulls say
Conmed Corp demonstrated strong financial performance, with General Surgery sales increasing by 8.7% to $206.9 million, surpassing consensus estimates. The company's operating margin saw a significant improvement, rising 280 basis points year-over-year to 18.6%, supported by gross margin expansion and operational efficiencies. Additionally, international sales of $142.6 million grew by 5.0%, reflecting positive momentum in both Orthopedic and General Surgery segments despite ongoing supply chain challenges.
Bears say
Conmed Corp faces a negative outlook largely due to projected revenue growth slowing to 4% or less, driven by disappointing sales in key product lines and challenges with new product launches. Additionally, management's downgraded guidance for 2025 revenue and earnings per share reflects ongoing supply chain difficulties that are anticipated to negatively impact profit margins. Furthermore, the risk factors identified, including weaker revenue growth, adverse currency impacts, and reduced hospital capital spending, contribute to a precarious financial position for the company.
This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.
CONMED (CNMD) Analyst Forecast & Price Prediction
Start investing in CONMED (CNMD)
Order type
Buy in
Order amount
Est. shares
0 shares